Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
66.0%
-
Total 13F principal
-
$334,700,000
-
Principal change
-
+$35,596,313
-
Total reported market value
-
$220,380,890
-
Number of holders
-
20
-
Value change
-
+$19,486,212
-
Number of buys
-
5
-
Number of sells
-
7
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q4 2023
As of 31 Dec 2023,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
20 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$334,700,000
in principal (par value) of the bond.
The largest 10 bondholders included
Context Capital Management, LLC, WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, UBS OCONNOR LLC, CITIGROUP INC, AVIVA PLC, CAPSTONE INVESTMENT ADVISORS, LLC, and BRAIDWELL LP.
This page lists
20
institutional bondholders reporting positions
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.